ABOUT ZERA MEDICAL

Colorectal cancer is one of the most preventable cancers in the world. The prep is why millions of people are not screened.

Zera Medical was founded to fix that.

OUR MISSION

To remove the single greatest barrier to colorectal cancer screening by replacing the most dreaded part of colonoscopy with a predictable, dignified, clinical-grade preparation experience that works every time.

THE STORY

Why we built ZeraFlow

15M+

COLONSCOPIES PERFORMED ANNUALLY IN U.S.¹

18–35%

COMPROMISED BY INADEQUATE BOWEL PREP ²

42%+

OF ADULTS DELAY OR AVOID SCREENING DUE TO PREP³

More than 15 million colonoscopies are performed in the United States each year. It is the gold standard for preventing colorectal cancer. Yet millions of eligible adults delay or skip screening—not because of the procedure, but because of the preparation.

For decades, patients have been sent home with large volumes of harsh laxatives, complicated instructions, and little clinical support. An uncomfortable, unpredictable process, managed alone. In 18–35% of cases, that process falls short, leading to compromised procedures, missed lesions, and costly repeat visits.

Zera Medical was built on a simple belief: bowel preparation should not be the patient’s responsibility—it should be the care team’s. ZeraFlow brings prep into the clinic, under supervision, with consistent and predictable results. A better experience for patients. A better procedure for physicians. A better outcome for everyone.

Several forces are converging at once

  • Rising incidence in younger adults

    Colorectal cancer rates are increasing among adults aged 45–55, the fastest-growing screening cohort. Updated guidelines now include patients 45 and older—adding millions who have never experienced prep before.⁴

  • GLP-1 medications complicate oral prep

    The rapid adoption of GLP-1 medications is making traditional prep less tolerable by slowing gastric emptying.⁵ A growing segment of patients now has a medical reason to avoid standard laxative regimens.

  • Provider pressure to improve efficiency

    GI practices and ASCs face increasing financial and operational strain from inadequate prep, repeat procedures, and day-of cancellations. ZeraFlow turns an unpredictable liability into a controlled, revenue-generating clinical step.

  • Consumer demand for dignified care

    Patients increasingly expect care that is convenient, comfortable, and modern. The next generation of screening patients has experienced better—and expects it.

ZeraFlow is not available everywhere yet.

We are completing FDA clearance and selecting our first U.S. clinic partners. Enter your information and we will notify you as soon as ZeraFlow is available near you.

¹ Widely corroborated. Primary: Ness RM et al. Journal of General Internal Medicine. 2007;22(10):1415–1421.
² Ness RM et al. American Journal of Gastroenterology. 2001;96:1797–1802. AND Bucci C et al. World Journal of Gastroenterology. 2014;20(23):6978–6990.
³ McLachlan SA, Clements A, Austoker J. Journal of Clinical Oncology. 2009;27(Suppl):S15.
⁴ CDC. Use of colorectal cancer screening tests, 2023. Preventing Chronic Disease. 2025.
⁵ AASLD/ACG/AGA/ASGE/NASPGHAN Multi-Society Statement. GLP-1 receptor agonists may be associated with delayed gastric emptying and safety concerns related to sedation and endoscopy. 2023. URL: https://gastro.org/news/gi-multi-society-statement-regarding-glp-1-agonists-and-endoscopy/ Kindel TL, et al. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Clinical Gastroenterology and Hepatology. 2024. DOI: https://doi.org/10.1016/j.cgh.2024.10.003
ZeraFlow is an investigational device. It has not been cleared or approved by the U.S. FDA and is not currently available for commercial sale in the United States.” This is confirmed present across all nine pages. Maintain it in all published versions.